Resveratrol for Alzheimer's disease
Christine Sawda1, Charbel Moussa1,2, R Scott Turner1,2
1Memory Disorders Program, Department of Neurology, Georgetown University, Washington, DC.
Annals of the New York Academy of Sciences
|August 18, 2017
Summary
Resveratrol, a SIRT1 activator, shows promise in Alzheimer's disease (AD) treatment by crossing the blood-brain barrier, altering biomarkers, and modulating immune responses. Further research is needed to confirm its safety and efficacy for AD and aging diseases.
Area of Science:
- Neuroscience
- Aging Research
- Pharmacology
Background:
- The amyloid hypothesis posits that amyloid accumulation causes Alzheimer's disease (AD).
- Molecular aging mechanisms are potential therapeutic targets for AD.
- Caloric restriction and sirtuin activators like resveratrol may prevent aging-related diseases, including AD.
Purpose of the Study:
- To evaluate the safety and efficacy of resveratrol in individuals with mild-to-moderate AD.
- To investigate resveratrol's effects on AD biomarkers and the CNS environment.
Main Methods:
- A randomized, double-blind, placebo-controlled, phase II clinical trial.
- Administration of resveratrol to participants with mild-to-moderate AD.
- Assessment of resveratrol levels in cerebrospinal fluid, safety, tolerability, biomarker changes, blood-brain barrier integrity, and immune response.
Main Results:
- Resveratrol was detected in cerebrospinal fluid at low nanomolar levels.
- The compound was found to be safe and well-tolerated.
- Resveratrol altered AD biomarker trajectories, preserved blood-brain barrier integrity, and modulated the CNS immune response.
Conclusions:
- Resveratrol demonstrates potential as a therapeutic agent for Alzheimer's disease.
- Further studies are required to establish the definitive safety and efficacy of resveratrol for AD and other aging-related diseases.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:26Atherosclerosis III: Management
482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
278
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
278
02:30siRNA - Small Interfering RNAs
18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K